tetano
Editor, Senior Moderator
Bull World Health Organ
. 2022 Aug 1;100(8):474-483.
doi: 10.2471/BLT.22.288073. Epub 2022 Jun 22.
COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran
Ali Hosseinzadeh[SUP] 1 [/SUP], Sajad Sahab-Negah[SUP] 2 [/SUP], Sairan Nili[SUP] 3 [/SUP], Roqayeh Aliyari[SUP] 4 [/SUP], Shahrbanoo Goli[SUP] 1 [/SUP], Mohammad Fereidouni[SUP] 5 [/SUP], Ali Alami[SUP] 6 [/SUP], Mohsen Shati[SUP] 7 [/SUP], Elham Ahmadnezhad[SUP] 8 [/SUP], Shiva Mehravaran[SUP] 9 [/SUP], Mansooreh Fateh[SUP] 10 [/SUP], Hamidreza Khajeha[SUP] 4 [/SUP], Zahra Emamian[SUP] 11 [/SUP], Elahe Behmanesh[SUP] 11 [/SUP], Sepideh Mahdavi[SUP] 1 [/SUP], Mostafa Enayatrad[SUP] 12 [/SUP], Parvin Mangolian Shahrbabaki[SUP] 13 [/SUP], Alireza Ansari-Moghaddam[SUP] 14 [/SUP], Abtin Heidarzadeh[SUP] 15 [/SUP], Fariba Shahraki-Sanavi[SUP] 14 [/SUP], Seyed Mohammad Hashemi Shahri[SUP] 16 [/SUP], Mahlagha Dehghan[SUP] 13 [/SUP], Mohammadreza Amini Moridani[SUP] 17 [/SUP], Hossein Sheibani[SUP] 18 [/SUP], Maryam Abbaszadeh[SUP] 18 [/SUP], Reza Jafari[SUP] 19 [/SUP], Maryam Valikhani[SUP] 18 [/SUP], Ehsan Binesh[SUP] 18 [/SUP], Hamid Vahedi[SUP] 18 [/SUP], Reza Chaman[SUP] 1 [/SUP], Rozita Khodashahi[SUP] 20 [/SUP], Mahnaz Amini[SUP] 21 [/SUP], Farahzad Jabbari Azad[SUP] 22 [/SUP], Fariborz Rezaeitalab[SUP] 2 [/SUP], Saeid Amel Jamehdar[SUP] 23 [/SUP], Ali Eshraghi[SUP] 24 [/SUP], Hamid Sharifi[SUP] 25 [/SUP], Seyed Mehdi Hashemi Bajgani[SUP] 26 [/SUP], Amin Mahdavi[SUP] 27 [/SUP], Abdollah Jafarzadeh[SUP] 1 2 [/SUP], Mehrdad Farokhnia[SUP] 1 3 [/SUP], Saeedeh Ebrahimi[SUP] 1 4 [/SUP], Abbas Pardakhti[SUP] 1 5 [/SUP], Ebrahim Ghaderi[SUP] 1 6 [/SUP], Hasan Soltani[SUP] 1 7 [/SUP], Sedigh Jadidoleslami[SUP] 1 8 [/SUP], Anoush Arianejad[SUP] 1 8 [/SUP], Hamed Gavili[SUP] 1 8 [/SUP], Borhan Moradveisi[SUP] 1 9 [/SUP], Dina Motamedi[SUP] 1 10 [/SUP], Hamed Zare[SUP] 5 [/SUP], Toba Kazemi[SUP] 1 11 [/SUP], Mohammad Hassan Emamian[SUP] 4 [/SUP]
Affiliations
Abstract
in English, French, Spanish, Arabic, Chinese, Russian
Objective: To investigate the incidence of coronavirus disease 2019 (COVID-19) cases, hospitalizations and deaths in Iranians vaccinated with either AZD1222 Vaxzevria, CovIran® vaccine, SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) or Sputnik V.
Methods: We enrolled individuals 18 years or older receiving their first COVID-19 vaccine dose between April 2021 and January 2022 in seven Iranian cities. Participants completed weekly follow-up surveys for 17 weeks (25 weeks for AZD1222) to report their COVID-19 status and hospitalization. We used Cox regression models to assess risk factors for contracting COVID-19, hospitalization and death.
Findings: Of 89 783 participants enrolled, incidence rates per 1 000 000 person-days were: 528.2 (95% confidence interval, CI: 514.0-542.7) for contracting COVID-19; 55.8 (95% CI: 51.4-60.5) for hospitalization; and 4.1 (95% CI: 3.0-5.5) for death. Compared with SARS-CoV-2 Vaccine (Vero Cell), hazard ratios (HR) for contracting COVID-19 were: 0.70 (95% CI: 0.61-0.80) with AZD1222; 0.73 (95% CI: 0.62-0.86) with Sputnik V; and 0.73 (95% CI: 0.63-0.86) with CovIran®. For hospitalization and death, all vaccines provided similar protection 14 days after the second dose. History of COVID-19 protected against contracting COVID-19 again (HR: 0.76; 95% CI: 0.69-0.84). Diabetes and respiratory, cardiac and renal disease were associated with higher risks of contracting COVID-19 after vaccination.
Conclusion: The rates of contracting COVID-19 after vaccination were relatively high. SARS-CoV-2 Vaccine (Vero Cell) provided lower protection against COVID-19 than other vaccines. People with comorbidities had higher risks of contracting COVID-19 and hospitalization and should be prioritized for preventive interventions.
. 2022 Aug 1;100(8):474-483.
doi: 10.2471/BLT.22.288073. Epub 2022 Jun 22.
COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran
Ali Hosseinzadeh[SUP] 1 [/SUP], Sajad Sahab-Negah[SUP] 2 [/SUP], Sairan Nili[SUP] 3 [/SUP], Roqayeh Aliyari[SUP] 4 [/SUP], Shahrbanoo Goli[SUP] 1 [/SUP], Mohammad Fereidouni[SUP] 5 [/SUP], Ali Alami[SUP] 6 [/SUP], Mohsen Shati[SUP] 7 [/SUP], Elham Ahmadnezhad[SUP] 8 [/SUP], Shiva Mehravaran[SUP] 9 [/SUP], Mansooreh Fateh[SUP] 10 [/SUP], Hamidreza Khajeha[SUP] 4 [/SUP], Zahra Emamian[SUP] 11 [/SUP], Elahe Behmanesh[SUP] 11 [/SUP], Sepideh Mahdavi[SUP] 1 [/SUP], Mostafa Enayatrad[SUP] 12 [/SUP], Parvin Mangolian Shahrbabaki[SUP] 13 [/SUP], Alireza Ansari-Moghaddam[SUP] 14 [/SUP], Abtin Heidarzadeh[SUP] 15 [/SUP], Fariba Shahraki-Sanavi[SUP] 14 [/SUP], Seyed Mohammad Hashemi Shahri[SUP] 16 [/SUP], Mahlagha Dehghan[SUP] 13 [/SUP], Mohammadreza Amini Moridani[SUP] 17 [/SUP], Hossein Sheibani[SUP] 18 [/SUP], Maryam Abbaszadeh[SUP] 18 [/SUP], Reza Jafari[SUP] 19 [/SUP], Maryam Valikhani[SUP] 18 [/SUP], Ehsan Binesh[SUP] 18 [/SUP], Hamid Vahedi[SUP] 18 [/SUP], Reza Chaman[SUP] 1 [/SUP], Rozita Khodashahi[SUP] 20 [/SUP], Mahnaz Amini[SUP] 21 [/SUP], Farahzad Jabbari Azad[SUP] 22 [/SUP], Fariborz Rezaeitalab[SUP] 2 [/SUP], Saeid Amel Jamehdar[SUP] 23 [/SUP], Ali Eshraghi[SUP] 24 [/SUP], Hamid Sharifi[SUP] 25 [/SUP], Seyed Mehdi Hashemi Bajgani[SUP] 26 [/SUP], Amin Mahdavi[SUP] 27 [/SUP], Abdollah Jafarzadeh[SUP] 1 2 [/SUP], Mehrdad Farokhnia[SUP] 1 3 [/SUP], Saeedeh Ebrahimi[SUP] 1 4 [/SUP], Abbas Pardakhti[SUP] 1 5 [/SUP], Ebrahim Ghaderi[SUP] 1 6 [/SUP], Hasan Soltani[SUP] 1 7 [/SUP], Sedigh Jadidoleslami[SUP] 1 8 [/SUP], Anoush Arianejad[SUP] 1 8 [/SUP], Hamed Gavili[SUP] 1 8 [/SUP], Borhan Moradveisi[SUP] 1 9 [/SUP], Dina Motamedi[SUP] 1 10 [/SUP], Hamed Zare[SUP] 5 [/SUP], Toba Kazemi[SUP] 1 11 [/SUP], Mohammad Hassan Emamian[SUP] 4 [/SUP]
Affiliations
- PMID: 35923277
- PMCID: PMC9306382
- DOI: 10.2471/BLT.22.288073
Abstract
in English, French, Spanish, Arabic, Chinese, Russian
Objective: To investigate the incidence of coronavirus disease 2019 (COVID-19) cases, hospitalizations and deaths in Iranians vaccinated with either AZD1222 Vaxzevria, CovIran® vaccine, SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) or Sputnik V.
Methods: We enrolled individuals 18 years or older receiving their first COVID-19 vaccine dose between April 2021 and January 2022 in seven Iranian cities. Participants completed weekly follow-up surveys for 17 weeks (25 weeks for AZD1222) to report their COVID-19 status and hospitalization. We used Cox regression models to assess risk factors for contracting COVID-19, hospitalization and death.
Findings: Of 89 783 participants enrolled, incidence rates per 1 000 000 person-days were: 528.2 (95% confidence interval, CI: 514.0-542.7) for contracting COVID-19; 55.8 (95% CI: 51.4-60.5) for hospitalization; and 4.1 (95% CI: 3.0-5.5) for death. Compared with SARS-CoV-2 Vaccine (Vero Cell), hazard ratios (HR) for contracting COVID-19 were: 0.70 (95% CI: 0.61-0.80) with AZD1222; 0.73 (95% CI: 0.62-0.86) with Sputnik V; and 0.73 (95% CI: 0.63-0.86) with CovIran®. For hospitalization and death, all vaccines provided similar protection 14 days after the second dose. History of COVID-19 protected against contracting COVID-19 again (HR: 0.76; 95% CI: 0.69-0.84). Diabetes and respiratory, cardiac and renal disease were associated with higher risks of contracting COVID-19 after vaccination.
Conclusion: The rates of contracting COVID-19 after vaccination were relatively high. SARS-CoV-2 Vaccine (Vero Cell) provided lower protection against COVID-19 than other vaccines. People with comorbidities had higher risks of contracting COVID-19 and hospitalization and should be prioritized for preventive interventions.